Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.

The National Institute for Health and Care Excellence (NICE) has decided to reconsult on draft guidance for Alzheimer’s treatments donanemab and lecanemab, six months after initially rejecting the ...

However, a new study has shown that two drugs - lecanemab and donanemab - could help patients stay independent by approximately 10-13 months in the early stage. Usually, in Alzheimer's disease ...

One described the approval of lecanemab as “no panacea” for patients, for example, while another went as far as to suggest that, in their eyes, donanemab offered “no net benefit” at all.

Systematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...

Your doctor might suggest taking one of the newer medications such as lecanemab or donanemab, which have been shown in clinical trials to clear plaque-causing amyloid proteins from the brain that ...

While researchers continue to work on a full cure for Alzheimer's disease, they're finding treatments that can help manage ...

Additional evidence has prompted NICE to launch a second consultation on its decision not to recommend new Alzheimer’s ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs and limited benefit. Stakeholders can submit feedback until March 27, 2025, ...

However, "they can lead to life-threatening events including what was likely three treatment-related deaths in each of the donanemab and lecanemab studies." ARIA with edema or effusions (ARIA-E ...

Today we’ve published further draft guidance for public consultation that continues to not recommend Alzheimer’s treatments donanemab and lecanemab. These cookies remember information that changes the ...

Patients who took lecanemab extended their time at home for an additional 10 months, while donanemab enabled them to live independently for eight more months, according to a WashU press release.